(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say. Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned…
Anthem Plans to Leave Obamacare Insurance Market in Ohio in 2018
(Reuters)—Anthem Inc., one of the largest sellers of Obamacare individual health insurance, will exit most of the Ohio market next year because of volatility and uncertainty about whether the government will continue to provide subsidies aimed at making the plans affordable, it said on Tuesday. Republicans are trying to cut off the subsidy payments in…
AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial
(Reuters)—U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments. Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study,…
Anti-Drug Antibodies May Affect RA Treatment
A recent study examined the level of anti-drug antibodies (ADAs) in RA patients taking the TNF inhibitors adalimumab, infliximab and etanercept. Study patients without ADAs experienced better clinical outcomes, while patients with detectable ADAs had significantly lower serum trough drug concentrations…
U.S. State, Local Government Lawsuits Over Opioids Face Uphill Battle
BOSTON (Reuters)—A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success. Ohio on Wednesday became the latest, and largest, state or local government to bring…
Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
(Reuters)—Pfizer Inc. has hiked the price of nearly a hundred drugs by an average of 20 percent so far this year in the U.S., the Financial Times reported on Friday. The U.S. drug maker raised the list price of 91 medicines—including that of its erectile dysfunction treatment, Viagra, and its pain drug, Lyrica—on June 1…
Older Adults May Stave Off Arthritis Knee Pain with Fiber
(Reuters Health)—Older people who eat the most fiber are at lower risk of developing knee pain and stiffness due to osteoarthritis (OA), new research shows.1 Diets rich in fiber from plant-based foods have clear health benefits, such as lower cholesterol, better-controlled blood sugar and a healthier weight, but most people in the U.S. don’t eat…
Voclosporin Promising for Lupus Nephritis
In a recent clinical trial, voclosporin proved safe and effective at both low and high doses as a treatment for lupus nephritis…
Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease
New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…
Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…
- « Previous Page
- 1
- …
- 423
- 424
- 425
- 426
- 427
- …
- 816
- Next Page »